Despite the Medicines and Healthcare products Regulatory Agency's endorsement of Kisunla, also known as donanemab, NICE argues that the drug's high price tag, compounded by intravenous administration ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...

The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...

Eli Lilly (LLY) announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...

Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side ...

The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for ...

The drug kept me feeling normal, but i’m scared about what happens next’ - Peter Almond finished a trial for Donanemab in ...

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...